PCSK9 and metabolic dysfunction-associated steatotic liver disease: In the context of non-alcoholic fatty liver disease (NAFLD), PCSK9 is upregulated by treating with olanzapine, which enhances hepatic sterol regulatory element–binding protein 1c (SREBP-1c) expression, leading to increased cholesterol intake and lipid synthesis, thereby contributing to hepatic steatosis [36].